Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, Bredel M, Stark GR, Rich JN, Bao S. Guryanova OA, et al. Among authors: mclendon re. Cancer Cell. 2011 Apr 12;19(4):498-511. doi: 10.1016/j.ccr.2011.03.004. Cancer Cell. 2011. PMID: 21481791 Free PMC article.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN. Goudar RK, et al. Among authors: mclendon re. Mol Cancer Ther. 2005 Jan;4(1):101-12. Mol Cancer Ther. 2005. PMID: 15657358
Gene expression profiling and genetic markers in glioblastoma survival.
Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M. Rich JN, et al. Among authors: mclendon re. Cancer Res. 2005 May 15;65(10):4051-8. doi: 10.1158/0008-5472.CAN-04-3936. Cancer Res. 2005. PMID: 15899794
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Reardon DA, et al. Cancer. 2005 Oct 1;104(7):1478-86. doi: 10.1002/cncr.21316. Cancer. 2005. PMID: 16088964 Free article. Clinical Trial.
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS. Rich JN, et al. Among authors: mclendon re. Clin Cancer Res. 2005 Nov 15;11(22):8145-57. doi: 10.1158/1078-0432.CCR-05-0319. Clin Cancer Res. 2005. PMID: 16299247
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. Sathornsumetee S, et al. Among authors: mclendon re. Cancer Res. 2006 Sep 1;66(17):8722-30. doi: 10.1158/0008-5472.CAN-06-0284. Cancer Res. 2006. PMID: 16951188
Second messenger systems in human gliomas.
McLendon RE, Turner K, Perkinson K, Rich J. McLendon RE, et al. Arch Pathol Lab Med. 2007 Oct;131(10):1585-90. doi: 10.5858/2007-131-1585-SMSIHG. Arch Pathol Lab Med. 2007. PMID: 17922598 Free article. Review.
371 results